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Abstract
Clinicians and researchers alike are increasingly interested in how best to personalize in-
terventions. A dynamic treatment regimen (DTR) is a sequence of pre-specified decision rules
which can be used to guide the delivery of a sequence of treatments or interventions that are
tailored to the changing needs of the individual. The sequential multiple-assignment random-
ized trial (SMART) is a research tool which allows for the construction of effective DTRs. We
derive easy-to-use formulae for computing the total sample size for three common two-stage
SMART designs in which the primary aim is to compare mean end-of-study outcomes for two
embedded DTRs which recommend different first-stage treatments. The formulae are derived
in the context of a regression model which leverages information from a longitudinal outcome
collected over the entire study. We show that the sample size formula for a SMART can be
written as the product of the sample size formula for a standard two-arm randomized trial, a
deflation factor that accounts for the increased statistical efficiency resulting from a longitudinal
analysis, and an inflation factor that accounts for the design of a SMART. The SMART design
inflation factor is typically a function of the anticipated probability of response to first-stage
treatment. We review modeling and estimation for DTR effect analyses using a longitudinal
outcome from a SMART, as well as the estimation of standard errors. We also present estima-
tors for the covariance matrix for a variety of common working correlation structures. Methods
are motivated using the ENGAGE study, a SMART aimed at developing a DTR for increasing
motivation to attend treatments among alcohol- and cocaine-dependent patients.
1 Introduction
Dynamic treatment regimens (DTRs) are sequences of pre-specified decision rules leading to courses
of treatment which adapt to a patient’s changing needs.1 DTRs operationalize clinical decision-
making by recommending particular treatments or intervention components to certain subsets of
patients at specific times.2 Consider the following example DTR which was designed to increase
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engagement with an intensive outpatient rehabilitation program (IOP) for patients with alcohol
and/or cocaine dependence: “Within a week of the participant becoming non-engaged in the IOP,
provide a phone-based session focusing on helping the patient re-engage in the IOP. At week 8,
look back at the participant’s engagement pattern over the past eight weeks. If the participant
continued to not engage, provide a second phone-based session, this time focusing on facilitating
personal choice (i.e., highlighting various treatment options the patient can choose from in addition
to IOP). Otherwise, provide no further contact.”3 Notice that the DTR recommends intervention
strategies for both engaged and non-engaged participants at week 8. Alternative names for DTRs
include adaptive treatment strategies4,5 and adaptive interventions,6,7 among others.
Scientists often have questions about how best to sequence and individualize interventions in the
context of a DTR. Sequential, multiple-assignment, randomized trials (SMARTs) are one type of
randomized trial design that can be used to answer questions at multiple stages of the development
of high-quality DTRs.8,9,10 The characteristic feature of a SMART is that some or all participants
are randomized more than once, often based on previously-observed covariates. Each randomization
corresponds to a critical question regarding the development of a high-quality DTR, typically related
to the type, timing, or intensity of treatment. SMARTs have been employed in a variety of fields,
including oncology,11,12,13 surgery,14,15 substance abuse,16 and autism17.
Most SMARTs contain an embedded “tailoring variable”, a pre-defined covariate observed dur-
ing treatment which determines whether or how a participant will be randomized in the next stage
of the SMART. For example, participants who “respond” to treatment may be re-randomized be-
tween different treatment options than participants who do not respond. SMARTs with embedded
tailoring variables also contain embedded DTRs; that is, by design, participants in the SMART
receive sequences of treatments which are consistent with the recommendations made by one or
more DTRs. Note that SMARTs need not contain an embedded tailoring variable; however, we
restrict our focus in this manuscript to those that do. We discuss this in more detail in section 2.
The comparison of two embedded DTRs which recommend different first-stage treatments is a
common primary aim for a SMART.7 There exist data analytic methods for addressing this aim
when the outcome is continuous,7 survival,18 binary,19 cluster-level20 and longitudinal.21,22 A key
step in designing a SMART, as with any randomized trial, is determining the sample size needed
to be able detect a desired effect with given power. However, there is no existing method for
determining sample size for such a comparison when the outcome is continuous and longitudinal.
Our primary contribution is tractable sample size formulae for SMARTs with a continuous
longitudinal outcome in which the primary aim is an end-of-study comparison of two DTRs which
recommend different first-stage treatments. Additionally, we present estimators for parameters in
the working covariance matrix used in the analysis methods developed by Lu et al.21
In section 2, we provide a brief overview of three common SMART designs and introduce a mo-
tivating example. Section 3 reviews the estimation procedure introduced by Lu et al., and extends
it by developing estimators for various working covariance structures.21 In section 4, we develop
and present sample size formulae for SMARTs in which the primary aim is a comparison of two
embedded DTRs which recommend different first-stage treatments using a continuous longitudinal
outcome. The sample size formulae are evaluated via simulation in section 5.
2 Dynamic Treatment Regimens and Sequential Multiple-Assignment
Randomized Trials
A DTR is a sequence of functions (“decision rules”), each of which takes as inputs a person’s
history up to the time of the current decision (including baseline covariates, adherence, responses
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to previous treatments, etc.) and outputs a recommendation for the next treatment.10 Consider
the example DTR in section 1. The recommended first-stage treatment is a phone-based session
with a focus on re-engagement with the IOP. At week 8, each participant’s history of engagement
is assessed, and an appropriate second-stage treatment is recommended. For participants who
have shown a pattern of continued non-engagement, the recommended second-stage treatment is
a second phone-based session focusing on personal choice. For all other participants, the DTR
recommends no further contact. The tailoring variable is an indicator as to whether or not the
participant demonstrated a pattern of continued non-engagement prior to week 8.
We consider two-stage SMARTs in which the primary outcome is continuous and repeatedly
measured in participants over the course of the study. Our examples refer to trials in which at least
one observation of the outcome is made in each stage, though that is not required for the estimation
method presented in section 3. For simplicity, we refer to the tailoring variable as response status
to first-stage treatment, and, in the second stage, we describe participants as “responders” or “non-
responders”. We denote a DTR embedded in a SMART with a triple of the form (a1, a2R, a2NR),
where a1 is an indicator for the recommended first-stage treatment, a2R an indicator for the second-
stage treatment recommended for responders, and a2NR the second-stage treatment recommended
for non-responders. Throughout, (a1, a2R, a2NR) is non-random and is used to index the DTRs
embedded in a SMART.
We introduce three common two-stage SMART designs in figure 1 which vary in the subsets
of participants who are re-randomized after the first stage. Each of these designs contains an
embedded tailoring variable, and thus, for the purposes of this manuscript, contains embedded
DTRs.
In design I, all participants are re-randomized. There are eight DTRs embedded in this design:
for example, the DTR which starts by recommending A, then recommends C for responders and F
for non-responders. Using the notation in figure 1, this DTR would be written (1, 1, -1). SMARTs
of this form have been run in the fields of drug dependence,23,24 smoking cessation,25 and childhood
depression,26 among others.
SMARTs using design II restrict the second randomization to only non-responders; that is,
only participants who have a certain value of the tailoring variable (here, “non-response”) are re-
randomized. This is perhaps the most common SMART design, and it has been utilized in the
study of ADHD,27 adolescent marijuana use,28 alcohol and cocaine dependence3, and more. There
are four embedded DTRs in this design. Because responders are not re-randomized, a2R is set to
zero for all embedded DTRs.
In design III, re-randomization is restricted to only non-responders who receive a particular
first-stage treatment. SMARTs of this type have been used to investigate cognition in children
with autism spectrum disorder17,29 and implementation of a re-engagement program for patients
with mental illness.30 There are three DTRs embedded in this design. Note that, as in design II,
responders are not re-randomized, so a2R is set to zero for all embedded DTRs. Furthermore, a2NR
is set to zero when a1 = −1, as non-responders to treatment B are not re-randomized.
For more information on various SMART designs and case studies for each type, see Lei, et
al.31
To illustrate our ideas, we use ENGAGE, a SMART designed to study the effects of offering
cocaine- and/or alcohol-dependent patients who did not engage in an IOP phone-based sessions
either geared toward re-engaging them in an IOP or offering a choice of treatment options.3 The
study recruited 500 cocaine- and/or alcohol-dependent adults who were enrolled in an IOP and
failed to attend two or more sessions in the first two weeks. ENGAGE is modeled on design II. In
the context of figure 1, treatment A was two phone-based motivational interviews focused on reen-
gaging the participant with the IOP (“MI-IOP”); treatment B was two phone-based motivational
3
Stage 1 Stage 2
C
A2R = 1
R
D
A2R = −1
A
A1 = 1
E
A2NR = 1
R
F
A2NR = −1
R
G
A2 = 1
R
H
A2 = −1
B
A1 = −1
I
A2 = 1
R
J
A2 = −1
Time 0 Time 1 Time 2
Responders
Non-Responders
Responders
Non-Responders
(I) All participants are re-randomized, regardless of
response status.
Stage 1 Stage 2
C
A2 = 0
D
A2 = 1
R
E
A2 = −1
F
A2 = 0
G
A2 = 1
R
H
A2 = −1
Time 0 Time 1 Time 2
A
A1 = 1
B
A1 = −1
R
Responders
Non-Responders
Responders
Non-Responders
(II) The second randomization is restricted to only
non-responders.
Stage 1 Stage 2
C
A2 = 0
A
D
A2 = 1
R
E
A2 = −1
F
A2 = 0
B
A1 = −1
G
A2 = 0
Time 0 Time 1 Time 2
A
A1 = 1
R
Responders
Non-Responders
Responders
Non-Responders
(III) The second randomization is restricted to only
non-responders to treatment A.
Figure 1: Three commonly-used two-stage SMART designs. Each design varies in choice of which
subsets of participants are re-randomized. Circled R indicates randomization, capital letters indi-
cate (potentially non-unique) treatments, and a– provides a coding system used to index embedded
DTRs.
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interviews geared towards helping the participant choose and engage with an intervention of their
choice (“MI-PC”). Participants who exhibited a pattern of continued non-engagement after eight
weeks were considered non-responders, and re-randomized to receive either MI-PC (treatments D
and G) or no further contact (treatments E and H). Responders were provided no further contact
(treatments C and F). Following the coding in figure 1, the example DTR from section 1 is labeled
(1, 0, 1).
An important continuous outcome in ENGAGE is “treatment readiness”. This is a measure of
a patient’s willingness and ability to commit to active participation in a substance abuse treatment
program. The score ranges from 8-40 and is coded so that higher scores indicate greater treatment
readiness. Measurements are taken at baseline, and 4, 8, 12, and 24 weeks after program entry.
3 Estimation
We extend the work of Lu and colleagues by offering more detailed guidance on the estimation
of model parameters used in computing quantities of interest on which to compare two embedded
DTRs.21 We first review the method below.
3.1 Marginal Mean Model
Consider a SMART design with embedded DTRs labeled by (a1, a2R, a2NR). Suppose we have
a longitudinal outcome Yi = (Yt1,i, . . . , YtT ,i), i = 1, . . . , n, observed such that Yt,i is measured
for each of n participants at each of T timepoints {tj : j = 1, . . . , T ; t1 < . . . < tT }. We do not
require that these timepoints be equally-spaced, though they must be common to all participants
in the study. Define t∗ ∈ {tj} to be the time of the measurement taken immediately before
the assessment of response status and second randomization. In ENGAGE, for example, T = 5,
{tj} = {0, 4, 8, 12, 24}, and t∗ = t3 = 8. Let Xi be a vector of mean-centered baseline covariates,
such as age at baseline, sex, etc., for the ith individual.
We are interested in E[Y
(a1,a2R,a2NR)
t | X], the marginal mean outcome at time t under DTR
(a1, a2R, a2NR) conditional on X. This is the mean outcome at time t had all individuals with
characteristics X been offered DTR (a1, a2R, a2NR). Recall that a DTR recommends treatments
for both responders and non-responders; therefore, E[Y
(a1,a2R,a2NR)
t | X] is marginal over response
status. Note that Y
(a1,a2R,a2NR)
t,i is a potential outcome: the value of the outcome Yt,i that would
be observed had participant i been treated according to the DTR (a1, a2R, a2NR).
We impose a modeling assumption on E[Y
(a1,a2R,a2NR)
t |X]; namely, that E[Y (a1,a2R,a2NR)t |X] =
µ
(a1,a2R,a2NR)
t (X;θ), where µ
(a1,a2R,a2NR)
t (X;θ) is a marginal structural mean model with unknown
parameters θ = (η>,γ>)>. We use η to represent a column vector of parameters indexing baseline
covariates, and γ is a column vector of coefficients on terms involving treatment effects; we discuss
in more detail below. As noted by Lu and colleagues, the sequential nature of treatment delivery
in SMARTs may suggest constraints on the form of µ
(a1,a2R,a2NR)
t (X;θ) which depend, in part, on
the design of the SMART.21 For instance, in ENGAGE, at time t = 0, no treatments have been
assigned, so all DTRs share a common mean. At times t = 4 and t = 8, the four embedded DTRs
differ only by recommended first-stage treatment; thus there are two means of Y
(a1,a2R,a2NR)
t at each
timepoint. Finally, for times t > t∗ = 8, each DTR has a different mean Y (a1,a2R,a2NR)t .
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An example marginal structural mean model for ENGAGE (and, more generally, design II) is
µ
(a1,a2R,a2NR)
t (X1;θ) = η1X1 + γ0 + 1{t ≤ t∗} (γ1t+ γ2a1t)
+ 1{t > t∗} (γ1t∗ + γ2t∗a1 + γ3(t− t∗) + γ4(t− t∗)a1
+γ5(t− t∗)a2NR + γ6(t− t∗)a1a2NR) ,
(1)
where 1{E} is the indicator function for the event E.
Using contrast coding, i.e., {a1, a2NR} ∈ {−1, 1}2, we can write
2γ2 = E
Y (1,0,·)tj − Y (1,0,·)tk
tj − tk −
Y
(−1,0,·)
tj
− Y (−1,0,·)tk
tj − tk |X
 , tj , tk ≤ t∗. (2)
This represents the difference in slopes of expected treatment readiness in the first stage of the
SMART between DTRs starting with different first-stage treatments (second-stage treatment is
arbitrary, as t < t∗). Also, we can interpret η1 as the difference in expected outcome Y
(a1,a2R,a2NR)
t
associated with a one-unit difference in baseline covariate X1, marginal over all embedded DTRs.
We present example models for designs I and III in the online supplement. For more on modeling
considerations for longitudinal outcomes in SMARTs, see Lu et al.21
3.2 Observed Data
Suppose we have data arising from a SMART with n participants. Let A1,i ∈ {−1, 1} be a random
variable which indicates first-stage treatment randomly assigned to participant i (i = 1, . . . , n), and
let Ri ∈ {0, 1} indicate whether the ith participant responded to A1,i, in which case Ri = 1, or not,
so Ri = 0. Define A2,i ∈ {−1, 1} to be the randomly-assigned second-stage treatment. Throughout,
we use uppercase A to denote random treatment assignments; lowercase a’s are non-random indices
used to denote embedded DTRs.
In design II, since only non-responders are re-randomized, we set A2,i = 0 for responders;
similarly for design III. We observe a continuous outcome Yt,i for each participant at each of T
timepoints. In general, the data collected on the ith individual over the course of the study are of
the form (
Xi, Y0, A1,i,Y[0<t≤t∗],i, Ri, A2,i,Y[t>t∗],i
)
,
where Y[u<t≤v],i is a vector consisting of all values of the outcome observed for the ith participant
between times u and v.
3.3 Estimating Equations
Our goal is to estimate and make inferences on θ, the length-p column vector of mean parameters
in the marginal structural mean model of interest. For notational convenience, let D be the set of
DTRs embedded in the SMART under study; for instance, in design II,
D = {(a1, a2R, a2NR) : a1 ∈ {−1, 1} , a2R = 0, a2NR ∈ {−1, 1}} .
This creates , which can be corrected using inverse-probability weighting.7,32,2
Let W (d)(A1,i, Ri, A2,i) be a weight associated with participant i and DTR d ∈ D defined as
W (d)(A1,i, Ri, A2,i) =
I(d)(A1,i, Ri, A2,i)
P (A1,i = a1)P (A2,i = a2 | A1,i = a1, Ri) , (3)
6
Table 1: Design-specific indicators for consistency with a given DTR d ∈ D.
Design I(d)(A1,i, Ri, A2,i)
I 1{A1,i = a1} (1{A2,i = a2R}Ri + 1{A2,i = a2NR} (1−Ri))
II 1{A1,i = a1} (Ri + 1{A2,i = a2NR} (1−Ri))
III 1{A1,i = a1} (1{a1 = −1}+ 1{a1 = 1} (Ri + 1{A2,i = a2NR} (1−Ri)))
where I(d)(A1,i, Ri, A2,i) is an indicator of whether participant i is consistent with DTR d. The
form of I(d)(A1,i, Ri, A2,i) depends on the particular SMART design under study; for each of the
designs in figure 1, these expressions are shown in table 1.
We use W (d)(A1,i, Ri, A2,i) to account for the facts that, in some SMARTs (e.g., designs II
and III) there is known imbalance in the proportion of responders and non-responders consistent
with each DTR, and that that some (or all) participants are consistent with more than one embed-
ded DTR.
In design II, for example, only non-responders to first-stage treatment are re-randomized; if all
randomizations are with probability 0.5, W (1,0,1)(1, 1, 0) = (.5 × 1)−1 = 2 and W (1,0,1)(1, 0, 1) =
(.5 × .5)−1 = 4. Note that in design I, all participants are re-randomized; hence, all participants
receive a weight of 4. The analyst may freely substitute W (d)(A1,i, Ri, A2,i) = I
(d)(A1,i, Ri, A2,i) in
this case.
Define D(d) (Xi) ∈ RT×p to be the Jacobian of µ(d)(Xi;θ) with respect to θ; i.e., D(d) (Xi) =
∂µ(d)(Xi;θ)/∂θ
T . Let V (d)(Xi; τ ) ∈ RT×T be a working covariance matrix for Y (d), conditional
on baseline covariates X, under DTR d ∈ D. Here, τ = (σ>,ρ>)> is a vector of parameters
indexing variance (σ) and correlation (ρ) components of the working covariance structure. We
discuss V (d)(Xi; τ ) in detail in section 3.4. We estimate θ by solving the estimating equations
0 =
1
n
n∑
i=1
∑
d∈D
[
W (d) (A1,i, Ri, A2,i) ·D(d)(Xi)>V (d)(Xi; τ )−1
(
Yi − µ(d)(Xi;θ)
)]
. (4)
We call the solution to equation (4) θˆ.
Under usual regularity conditions for M -estimators (see, e.g., van der Vaart, theorem 5.4.1)33
and given data from a SMART (see appendix A), θˆ is consistent for θ. Furthermore,
√
n
(
θˆ − θ
)
has an asymptotic multivariate normal distribution:
√
n
(
θˆ − θ
)
⇒ N (0,B−1MB−1) ,
where
B := E
[∑
d∈D
W (d) (A1,i, Ri, A2,i)D
(d)(Xi)
>V (d)(Xi; τ )−1D(d)(Xi)
]
∈ Rp×p (5)
and
M := E
(∑
d∈D
W (d) (A1,i, Ri, A2,i)D
(d)(Xi)
>V (d)(Xi; τ )−1
(
Yi − µ(d)(Xi;θ)
))⊗2 ∈ Rp×p,
(6)
with Z⊗2 = ZZ>. Proofs of these claims are available in the supplement. Note that θˆ is consistent
for θ regardless of the chosen structure of V (d)(X; τ ); however, we conjecture that choices of
V (d)(X; τ ) closer to the true covariance matrix Var(Y (d)) will yield more efficient estimates.
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Table 2: Correlation estimators for selected working correlation structures, assuming con-
stant within-person variance over time. d ∈ D is an embedded DTR, W (d)i is shorthand for
W (d)(A1,i, Ri, A2,i), and eˆ
(d)
i,t (θˆ) is the estimated residual Yi,t − µ(d)t (Xi; θˆ).
Cor. structure Cor(Y
(d)
tj
, Y
(d)
tk
) Estimator
AR(1)
{
1 tj = tk(
ρ(d)
)|j−k|
tj 6= tk
ρˆ(d) =
∑n
i=1W
(d)
i
∑T−1
m=1 eˆ
(d)
i,tm
(θˆ)eˆ
(d)
i,tm+1
(θˆ)
(σˆ(d))
2·n·(T−1)
Exchangeable
{
1 tj = tk
ρ(d) tj 6= tk ρˆ
(d) =
∑n
i=1W
(d)
i
∑
l<m eˆ
(d)
i,tl
(θˆ)eˆ
(d)
i,tm
(θˆ)
(σˆ(d))
2·n·T (T−1)/2
Unstructured
{
1 tj = tk
ρ
(d)
tj ,tk
tj 6= tk ρˆ
(d)
tj ,tk
=
∑n
i=1W
(d)
i eˆ
(d)
i,tj
(θˆ)eˆ
(d)
i,tk
(θˆ)
(σˆ(d))
2·n
3.4 Estimation of the Working Covariance Matrix
Decisions regarding the structure of V (d)(X; τ ) should be made by the scientist according to
existing knowledge regarding the within-person covariance structure of Y (d). In general, for an
embedded DTR d ∈ D, V (d)(X; τ ) takes the form
V (d)(X;σ,ρ) = S(d)(σ)1/2R(d)(ρ)S(d)(σ)1/2,
where S(d)(σ)1/2 ∈ RT×T is a diagonal matrix with diagonal entries σ(d)t1 , . . . , σ
(d)
tT
, where σ
(d)
tj
=
Var(Y
(d)
tj
), and R(d)(ρ) ∈ RT×T is a working correlation matrix for Y (d). Note that this notation
allows for different working covariance structures for each DTR, as well as non-constant variances
of the longitudinal outcome across time.
We propose the following procedure to estimate V (d)(X; τ ). First, estimate θ by solving equa-
tion (4) using the T × T identity matrix as V (d)(X; τ ) for all d ∈ D. Call the solution θˆ(0). Next,
use θˆ(0) to estimate σ
(d)
t as follows
(
σˆ
(d)
t
)2
=
∑n
i=1W
(d) (A1,i, Ri, A2,i)
(
Yi,t − µ(d)t
(
Xi; θˆ(0)
))2
∑n
i=1W
(d) (A1,i, Ri, A2,i)− p
, (7)
where p is the dimension of θ. If the scientist believes that this variance is constant over time for
each DTR, the estimator in equation (7) can be averaged over time; one can also average over DTR
if one believes the variance is constant across all embedded DTRs. Estimators for ρ(d) vary with
choice of correlation structure R(d)(ρ); we present estimators for selected structures in table 2.
Note that the denominator in equation (7) must be positive. For a fixed DTR d ∈ D, the
sum of the weights is, in expectation, the total sample size n (see supplement). Therefore, the
denominator is approximately n − p, as in the usual mean squared error in multiple regression,
for example. We recommend that analysts choose appropriately parsimonious marginal structural
mean models (i.e., p < n) to ensure that equation (7) is positive.
To complete the estimation procedure, we again solve equation (4), this time using Vˆ (d)(X; τˆ ) =
S(d)(σˆ)1/2R(d)(ρˆ)S(d)(σˆ)1/2 as the working covariance matrix. This process can be further iterated,
as suggested by Liang and Zeger;34 we call the final estimate of the model parameters θˆ.
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4 Sample Size Formulae for End-of-Study Comparisons
Often, longitudinal outcomes are collected in trials to improve the efficiency of the primary aim
analysis, even when comparing two treatment groups on the mean of some summary measure such
as the end-of-study observation.35 Fitting a longitudinal regression model and using the result
to estimate the difference in mean summary measure improves efficiency of the comparison by
leveraging within-person correlation (see, e.g. Fitzmaurice et al., section 2.5).36 Furthermore, this
approach allows investigators to simultaneously address secondary aims using the same regression
model.
As with standard randomized clinical trials, a common primary aim of a SMART is the compar-
ison of mean end-of-study outcomes for two embedded DTRs which recommend different first-stage
treatments12,18,31,37. We now present sample size formulae for SMARTs with longitudinal outcomes
in which this is the primary aim, addressed using the general estimation procedure of section 3;
that is, using a regression approach which includes all observed outcome data. We restrict our
focus to two-stage SMARTs in which the outcome is observed at three timepoints – baseline, just
prior to the second randomization, and at the end of the study – and in which all randomizations
occur with probability 0.5. Additionally, we consider a saturated, piecewise-linear mean structure
µ(d)(θ) similar to model (1).
Recall from section 3.1 that θ is a p-vector of parameters which indexes a marginal structural
mean model for the treatment effects in a SMART. Let c be a length-p contrast vector so that the
null hypothesis of interest takes the form
H0 : c
>θ = 0,
which we will test against an alternative of the form H1: c
>θ = ∆. To compare mean end-of-
study outcomes between two embedded DTRs which recommend different first-stage treatments,
the estimand of interest is
c>θ = E
[
Y
(1,a2R,a2NR)
tT
− Y (−1,a′2R,a′2NR)tT
]
, (8)
for some choice of a2R, a
′
2R, a2NR, and a
′
2NR. For example, to test equality of mean end-of-
study outcomes for DTRs (1, 0, 1) and (-1, 0, -1) in design II under model (1) (assuming no X,
{tj} = {0, 1, 2}, t∗ = 1), the estimand is the linear combination c>γ, where c> = (0, 0, 2, 0, 2, 2, 0).
We employ a 1-degree of freedom Wald test. The test statistic is
Z =
√
nc>θˆ
σc
,
where σc =
√
c>B−1MB−1c. Under the null hypothesis, by asymptotic normality of
√
n
(
θˆ − θ
)
,
the test statistic follows a standard normal distribution.
Define δ to be the standardized effect size as described by Cohen for an end-of-study comparison,
i.e.,
δ =
∆
σ
, (9)
where σ = Var(Y
(d)
t ) (see working assumption A2 below).
38
In order to simplify the form of σc and obtain tractable sample size formulae, we make the
following working assumptions (A1 and A2):
A1 Constrained conditional covariance matrices for DTRs under comparison.
9
(a) The variability of Y
(d)
t around the DTR mean µ
(d)
t (θ) among non-responders is no more
than the variance of Y
(d)
t unconditional on response; i.e.,
E
[(
Y
(d)
t − µ(d)t (θ)
)2 | R(a1) = 0] ≤ E [(Y (d)t − µ(d)t (θ))2] ,
for all t > t∗ and DTRs d ∈ D under study.
(b) For times ti ≤ tj ≤ t∗, response status is uncorrelated with products of residuals; i.e,
Cov
(
R(a1),
(
Y
(d)
ti
− µ(d)ti (θ)
)(
Y
(d)
tj
− µ(d)tj (θ)
))
= 0.
for DTRs d ∈ D under study.
(c) The covariance between the end-of-study measurement and the measurements prior to
the second stage among responders is less than or equal to the same quantity among
non-responders:
Cov
(
Y
(d)
t , Y
(d)
tT
| R(a1) = 1
)
≤ Cov
(
Y
(d)
t , Y
(d)
tT
| R(a1) = 0
)
for DTRs d ∈ D under study and t ≤ t∗.
A2 Exchangeable marginal covariance structure. The marginal variance of Y (d) is constant across
time and DTR, and has an exchangeable correlation structure with correlation ρ, i.e.,
Var
(
Y (d)
)
= Σ = σ2

1 ρ · · · ρ
ρ 1 · · · ρ
...
...
. . .
...
ρ ρ · · · 1

T×T
for all d ∈ D.
Note that the above are working assumptions which we do not believe hold in general. We
will see in sections 5 and 6 that sample size formula (10) (given below) is robust to moderate
violations of working assumption A1 and that inputs to the formula can be adjusted in a way
to accommodate violations of working assumption A2. A working assumption similar to A1(a) is
commonly made in developing sample-size formulae for SMARTs with outcomes collected once at
the end of the study.39,19,20 Working assumptions A1(b) and A1(c) impose further constraints on
the covariance of the outcome conditional on response and allow for tractable sample size formulae.
We believe working assumption A1(b) is approximately satisfied in most common definitions of
response (see the supplement). Working assumption A2 is not strictly necessary, but is used to
simplify the sample size formulae and facilitate easier elicitation of parameters. See section 6 for
more discussion.
Working assumption A1 arises specifically as a consequence of unequal weights in equation (4)
(i.e., when there exists imbalance between responders and non-responders, by design); therefore,
the assumption is not necessary in design I, and can be relaxed to apply to only the two DTRs
in which non-responders are re-randomized in design III. See appendix B for more details on how
this assumption is used. Furthermore, working assumption A2 cannot be satisfied in design I if all
eight embedded DTRs have unique means.
10
Table 3: Design effects for sample size formula (10). ra1 = P (R
(a1) = 1) is the response rate to
first-stage treatment a1.
.
Design Design effect Conservative design effect
I 2 2
II 12(2− r1) + 12(2− r−1) 2
III 12(3− r1) 32
Under working assumptions A1 and A2, the minimum-required sample size to detect a stan-
dardized effect size δ with power at least 1− β and two-sided type-I error α is
n ≥ 4
(
z1−α/2 + z1−β
)2
δ2
· (1− ρ2) ·DE, (10)
where DE is a SMART-specific “design effect” for an end-of-study comparison (see table 3). These
design effects are functions of response rates P (R(a1) = 1) = ra1 ; if researchers do not have well-
informed estimates of these probabilities, they may use a conservative design effect in which ra1 = 0
for a1 ∈ {−1, 1}.
Note that the first term in formula (10) is the typical sample size formula for a traditional two-
arm randomized trial with a continuous end-of-study outcome and equal randomization probability.
The middle term is due to the within-person correlation in the outcome, and is identical to the
corresponding correction term for GEE analyses sized to detect a group-by-time interaction when
there is no baseline group effect (see, e.g., Fitzmaurice et al., ch. 2036).
5 Simulations
We conducted a variety of simulations to assess the performance of sample size formula (10). We are
interested in the empirical power for a comparison of the DTR which recommends only treatments
indicated by 1 and the DTR which recommends only treatments indicated by −1 when the study
is sized to detect an effect size of δ. In ENGAGE, this might correspond to a comparison of mean
end-of-study outcomes under the DTR which recommends MI-IOP in the first stage, no further
contact for engagers, and MI-PC in the second stage for continued non-engagers versus the mean
end-of-study outcomes under the regimen which recommends MI-PC in the first-stage, then no
further contact for both engagers and non-engagers.
We consider four types of scenarios: first, when no assumptions are violated; second, when each
of working assumptions A1(a) to A1(c) are violated; finally, when the working correlation structure
is misspecified, in violation of working assumption A2. In each scenario, sample sizes are computed
based on nominal power 1− β = 0.8 and two-sided type-I error α = 0.05.
We believe sample sizes from formula (10) will be slightly conservative when all assumptions are
satisfied, as formula (10) is an interpretable upper bound on a sharper formula given in appendix B
and the supplement. For design I, we do not expect power to be affected by violations of working
assumption A1, as the assumption arises as a consequence of over- or under-representation of
responders and non-responders consistent with a particular DTR (see appendix B). Since there is
no such imbalance in design I, working assumption A1 is not applicable. Similarly, in design III,
only non-responders to one first-stage treatment are re-randomized, so we expect that empirical
power will decrease slightly, but not seriously, when violating working assumption A1. We expect
empirical power to suffer most severely when violating this working assumption in design II.
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We further conjecture that scenarios in which the true within-person correlation structure of
Y (d) is autoregressive, sample sizes from formula (10) will be very anti-conservative. Under an
AR(1) correlation structure, less information about the end-of-study outcome is provided by the
baseline measure than would be under an exchangeable correlation structure. Since, by using
formula (10), we have assumed more information is available from earlier measurements than is
actually the case, we will be underpowered. Similarly, we expect over-estimation of ρ in formula (10)
to lead to anti-conservative sample sizes.
5.1 Data Generative Process
For each simulation, the true marginal mean model is as in model (1) for design II; analogous
models are used for designs I and III – see the supplement for examples. We do not include
baseline covariates X; this is a conservative approach, as we believe that adjustment for prognostic
covariates typically will increase power (see, eg., Kahan et al.40). Estimates of marginal means
from ENGAGE were used to inform a reasonable range of “true” means from which to simulate,
though the scenarios presented here are not designed to mimic ENGAGE exactly. All simulations
take T = 3 and values of γ and σ are chosen to achieve δ = 0.3 or δ = 0.5 (“small” and “moderate”
effect sizes, respectively).
Data were generated according to a conditional mean model which, when averaged over response,
yields the marginal model of interest. Potential outcomes Y
(d)
t,i were simulated from appropriately-
parameterized normal distributions (see appendix C for details); data were “observed” by selecting
the potential outcome corresponding to treatment assignment as generated from a Bernoulli(0.5)
distribution.
We consider three mechanisms for generating response status. In the first, “R⊥⊥”, response
is generated from a Bernoulli(ra1) distribution, where ra1 = P (R
(a1) = 1), independently of all
previously-observed data. In the second and third scenarios (“R+” and “R−”, respectively), re-
sponse status is still generated from a Bernoulli distribution, but each individual is assigned a
probability of response correlated with their observed value of Y1. These correlations are either
positive or negative, depending on the response model. This is intended to mimic different coding
choices for Y , in the sense of responders tending to have higher or lower values of Y1 than non-
responders. For details of how these are generated, see appendix C, which also contains additional
details regarding the data generative models used. In the supplement, we present simulation results
under additional models for response.
For each simulation scenario, we compute upper and lower bounds on allowable values of
Var(Y
(d)
2 | R(a
(d)
1 ) = 1), beyond which it is not possible to either achieve the desired marginal
variance, or which induces violation of working assumption A1(a). The results shown in the cor-
responding column of table 4 were generated when responders’ variances were set to 75% of the
lower bound beyond which the fixed marginal variance forces E[(Y
(d)
t − µ(d)t (θ))2 | R(a1) = 0] ≥ σ2.
Violation of working assumption A1(b) was induced by defining response status as
R(a1) = 1
{
Y
(d)
1 ∈
(
−∞, κlowa1
]
∪
[
κhigha1 ,∞
)}
, (11)
where κlow and κhigh are chosen to be the r/2 and (1− r/2)th quantiles of the N
(
µ
(d)
1 , σ
2
)
distri-
bution, respectively. This ensures control on response probability while also inducing large positive
correlation between R(a1) and (Y
(d)
1 − µ(d)1 )2.
Violation of working assumption A1(c) was induced by choosing Cor(Y
(d)
t , Y
(d)
2 | R(a1) = 1) >
Cor(Y
(d)
t , Y
(d)
2 | R = 0) while keeping respective variances fixed. In our generative model, it was
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difficult to exert precise control over these quantities when response was related to prior outcomes;
as such, these violations were induced under the R⊥⊥ response model.
There exist natural constraints on how much larger than Cov(Y
(d)
t , Y
(d)
2 | R = 0) the responders’
covariance can be while ensuring that (1) all conditional covariance matrices are positive definite
and (2) Cov(Y
(d)
t , Y
(d)
2 | R = 0) ≥ 0 for t = 0, 1. These constraints vary with ρ. We choose
Cor(Y
(d)
t , Y
(d)
2 | R(a1) = 1) such that Cov(Y (d)t , Y (d)2 | R(a1) = 1) is the midpoint between the
minimum covariance for which the assumption is violated and the maximum covariance allowed by
the aforementioned constraints.
5.2 Simulation Results
Simulation results based on 3,000 simulated data sets are compiled in table 4. We find that sample
size formula (10) performs as expected when all assumptions are satisfied. Empirical power is not
significantly less than the target power of 0.8, per a one-sided binomial test with level 0.05. The
sample size is, as expected, often conservative, particularly when within-person correlation is high.
Table 4: Sample sizes and empirical power results for an end-of-study comparison of the DTR
recommending only treatments indexed by 1 and that which recommends only treatments indicated
by −1. δ is the true standardized effect size as defined in equation (9), r is the common probability
of response to first-stage treatment, and ρ is the true exchangeable within-person correlation. n
is computed using formula (10) with α = 0.05 and β = 0.2. R⊥⊥ refers to a generative model in
which response status is independent of all prior outcomes; R+ and R− refer to generative models
in which response is positively or negatively correlated with Y1, respectively. All violation scenarios
assume the R+ generative model, except working assumption A1(c). Results are the proportion of
3000 Monte Carlo simulations in which we reject H0 : c
>θ = 0 at the 5% level.
Empirical power
A1 and A2 satisfied Violation of A1 Violation of A2
Design δ r ρ n R⊥⊥ R+ R− A1(a) A1(b) A1(c) True AR(1)
I 0.3 0.4 0.0 698 0.798 0.807 0.803 0.798 0.796 ‡ ‡
0.3 635 0.819 0.817 0.800 0.820 0.804 0.815 0.780∗
0.6 447 0.815 0.862 0.773∗ 0.865 0.817 0.827 0.728∗
0.8 252 0.835 0.925 0.733∗ † † 0.840 0.721∗
0.6 0.0 698 0.796 0.799 0.806 0.800 0.791 ‡ ‡
0.3 635 0.808 0.813 0.792 0.824 0.805 0.807 0.775∗
0.6 447 0.833 0.856 0.798 0.859 0.831 0.838 0.727∗
0.8 252 0.827 0.901 0.758∗ † † 0.835 †
0.5 0.4 0.0 252 0.799 0.801 0.798 0.798 0.801 ‡ ‡
0.3 229 0.813 0.815 0.797 0.814 0.811 0.814 0.771∗
0.6 161 0.824 0.872 0.789 0.868 0.833 0.843 0.742∗
0.8 91 0.843 0.931 0.734∗§ 0.926 † 0.839§ 0.725∗
0.6 0.0 252 0.796 0.797 0.810 0.792 0.802 ‡ ‡
0.3 229 0.817 0.815 0.808 0.811 0.823 0.823 0.771∗
0.6 161 0.838 0.859 0.790 0.861 0.832 0.837 0.749∗
0.8 91 0.835§ 0.896 0.765∗§ 0.896 † 0.859 †
II 0.3 0.4 0.0 559 0.801 0.801 0.808 0.778∗ 0.803 ‡ ‡
0.3 508 0.804 0.813 0.831 0.800 0.797 0.798 0.795
continued
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Empirical power
A1 and A2 satisfied Violation of A1 Violation of A2
Design δ r ρ n R⊥⊥ R+ R− A1(a) A1(b) A1(c) True AR(1)
0.6 358 0.817 0.819 0.834 0.807 0.759∗ 0.788 0.811
0.8 201 0.836 0.814 0.836 0.809 † 0.792 0.806
0.6 0.0 489 0.804 0.796 0.793 0.736∗ 0.810 ‡ ‡
0.3 445 0.797 0.804 0.818 0.758∗ 0.795 0.780∗ 0.804
0.6 313 0.824 0.831 0.844 0.793 0.752∗ 0.770∗ 0.824
0.8 176 0.845 † † 0.754∗ † 0.776∗ 0.842
0.5 0.4 0.0 201 0.801 0.800 0.802 0.768∗ 0.794 ‡ ‡
0.3 183 0.813 0.800 0.819 0.790 0.813 0.796 0.803
0.6 129 0.814 0.828 0.833 0.810 0.763∗ 0.799 0.815
0.8 73 0.839 0.841 0.852 0.829 † 0.795 0.804
0.6 0.0 176 0.807 0.799 0.796 0.733∗ 0.808 ‡ ‡
0.3 160 0.816 0.815 0.821 0.767∗ 0.808 0.802 0.812
0.6 113 0.829 0.830 0.837 0.792 0.765∗ 0.770∗ 0.817
0.8 64 0.845§ † † 0.783∗§ † 0.789§ †
III 0.3 0.4 0.0 454 0.806 0.813 0.806 0.782∗ 0.794 ‡ ‡
0.3 413 0.815 0.809 0.814 0.789 0.800 0.800 0.775∗
0.6 291 0.821 0.811 0.818 0.794 0.783∗ 0.787∗ 0.687∗
0.8 164 0.824 0.812 0.839 0.812 † 0.802 0.637∗
0.6 0.0 419 0.813 0.814 0.817 0.781∗ 0.769∗ ‡ ‡
0.3 381 0.823 0.812 0.808 0.776∗ 0.791 0.795 0.771∗
0.6 268 0.823 0.817 0.844 0.807 0.750∗ 0.754∗ 0.709∗
0.8 151 0.820 † † 0.803 † 0.784∗ †
0.5 0.4 0.0 164 0.808 0.804 0.795 0.776∗ 0.802 ‡ ‡
0.3 149 0.822 0.815 0.827 0.811 0.791 0.805 0.789
0.6 105 0.811 0.810 0.812 0.810 0.798 0.785∗ 0.698∗
0.8 59 0.838 † 0.823 0.845 † 0.817§ 0.684∗
0.6 0.0 151 0.798 0.809 0.803 0.778∗ 0.772∗ ‡ ‡
0.3 138 0.812 0.809 0.814 0.800 0.782∗ 0.799 0.778∗
0.6 97 0.803§ 0.812 0.826§ 0.826§ 0.762∗ 0.774∗§ 0.705∗§
0.8 55 0.826§ † † 0.837§ † 0.797§ †
∗ Statistically significantly less than 0.8 at the 5% level.
† Our data generative model could not accommodate this scenario (see appendix C).
‡ Violation of this working assumption is not applicable when ρ = 0.
§ Fewer than 3000 simulations generated data in which all treatment sequences were observed.
There may be some concern that, for high within-person correlation, formula (10) is overly
conservative; should this concern arise, we recommend use of the sharper formulae presented in
the supplement. The difference between the sharper formulae and formula (10) is maximized when
ρ = (1 +
√
5)/2 ≈ 0.62, so we expect to see the largest differences in power between formula (10)
and the sharp formula when we set ρ = 0.6.
When all working assumptions are satisfied, we see that empirical power forR+ andR− scenarios
are similar or slightly higher than under the R⊥⊥ model. In general, there do not appear to be
practical differences in empirical power between the response models.
As conjectured, violating working assumption A1(a) does not impact empirical power in design I
(compare the results to column “R+”). For design II, empirical power is consistently less than the
nominal value when working assumption A1(a) is violated. However, while the empirical power is
often statistically significantly less than 0.8, for practical purposes the loss of power is relatively
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small. For design III, we notice small reductions in power relative to scenarios in which both working
assumptions A1 and A2 are satisfied, though the conservative nature of formula (10) appears to
protect against more severe loss of power. This suggests that our sample size formula is moderately
robust to reasonable violations of A1(a).
For small ρ, we see no meaningful change in empirical power when violating working assump-
tion A1(b). However, as ρ increases, this also leads to increased correlation between response
and the other products of first-stage residuals, which increases the severity of the violation. For
ρ = 0.6, we see noticeable, but not extreme, departures from nominal power. When ρ = 0.8, our
generative model was not able to violate working assumption A1(b) without also violating working
assumption A1(a); as such, we omit those results.
Interestingly, as can be seen in the supplement, defining non-response as in equation (11) (i.e.,
replacing R(a1) with 1 − R(a1)) leads to higher-than-nominal power. When there exists negative
correlation between response and products of squared first-stage residuals, the form of σ2c derived
in appendix B is more conservative, leading to increased power.
Simulation results show that our sample size formula is quite robust to violations of working
assumption A1(c) for low-to-moderate within-person correlations; at high correlations, the empirical
power is statistically significantly less than 0.8. However, as with working assumption A1(a), the
practical reduction in power is relatively small.
The final column of table 4 suggests that formula (10) is highly sensitive to violations of working
assumption A2 in regards to the true correlation structure. In particular, when the true correlation
structure is not exchangeable with correlation ρ and is instead AR(1) with correlation ρ, empirical
power is substantially lower than the target of 0.8, particularly as ρ increases. This is unsurprising:
as our assumed exchangeable ρ increases, the difference between the assumed and actual correlation
between the end-of-study measurement and earlier measurements increases, leading to more severe
loss of power.
Note that when within-person correlation is high, sample size becomes rather small. Since the
method presented here is based on asymptotic normality, we caution the reader that small sample
sizes (e.g., n < 100) provided by formula (10) may be quite sensitive to violation of the working
assumptions.
In figure 2, we examine the effect on empirical power of misspecifying the within-person cor-
relation. Analytically, we see from formula (10) that if the assumed ρ is smaller than the true
within-person correlation, the sample size will be conservative. On the other hand, when the as-
sumed ρ in formula (10) is larger than the true correlation, the sample size will be anti-conservative.
Figure 2 shows plots of empirical power against the difference between the assumed within-person
correlation ρguess and the true ρ. For small ρguess, formula (10) appears to be quite robust to
misspecification of ρ; however, as ρguess increases, the formula becomes highly sensitive to such a
violation of working assumption A2. This is supported analytically, since formula (10) is a function
of ρ2guess.
6 Discussion
We have derived sample size formulae for SMART designs in which the primary aim is a comparsion
of two embedded DTRs that begin with different first-stage treatments on a continuous, longitudinal
outcome. We derived the formulae for three common SMART designs.
The sample size formula is the product of three components: (1) the formula for the minimum
sample size for the comparison of two means in a standard two-arm trial (see, e.g., Friedman et
al.,41 page 147), (2) a deflation factor of 1−ρ2 that accounts for the use of a longitudinal outcome,
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Figure 2: Empirical power versus the difference between the true within-person correlation ρ and
hypothesized correlation ρguess used to compute sample size. Results are shown for design II with
a hypothesized response rate of 0.4, and sample size was chosen to detect standardized effect
size δ = 0.3 for the comparison of DTRs (1, 0, 1) and (-1, 0, -1). Each point is based on 3000
simulations with target power 0.8 and significance level 0.05. Results are similar for designs I
and III and different values of δ and r.
and (3) a SMART-specific “design effect”, an inflation factor that accounts for the SMART design.
The SMART design effect can be interpreted as the cost of conducting the SMART relative to
conducting a standard two-arm randomized trial of the two DTRs which comprise the primary aim.
The benefit of conducting a SMART (relative to the standard two-arm randomized trial) is the
ability to answer additional, secondary questions that are useful for constructing effective DTRs.
For example, such questions may focus on one or more of the other pairwise comparisons between
DTRs, on whether the first- and second-stage treatments work synergistically to impact outcomes
(e.g., a test of the null that γ6 = 0 in model (1)), or may focus on hypothesis-generating analyses
that seek to estimate more deeply-tailored DTRs.42,43,44
The formulae are expected to be easy-to-use for both applied statistical workers and clinicians.
Indeed, inputs α, β, and ∆ are as in the sample size formula for a standard z-test. Furthermore,
estimates of ρ, ra1 , and σ are often readily available from the literature or can be estimated using
data from prior studies (e.g., prior randomized trials, or external pilot studies).
We make a number of recommendations concerning the use of the formulae; in particular, how
best to use the formulae conservatively in the absence of certainty concerning prior estimates of ρ,
ra1 , and/or the structure of the variance of the repeated measures outcome. First, in designs II
and III, if there is uncertainty concerning the response rate (e.g., response rate estimates are based
on data from smaller prior studies), one approach is to err conservatively by assuming a smaller-
than-estimated response rate. In both designs, the most conservative approach is to assume a
response rate of zero.
Second, as in standard randomized trials in which the primary aim is a pre-post comparison, the
required sample size decreases as the hypothesized within-person correlation increases.45 Therefore,
if the hypothesized ρ is larger than the true ρ, the computed sample size will be anti-conservative,
resulting in an under-powered study. Indeed, we see this in the results of the simulation experiment
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(see figure 2). Here, again, one approach is to err conservatively towards smaller values of ρ.
Finally, working assumption A2 (concerning the variance of the repeated measures outcome)
may be seen as overly restrictive in the imposition of an exchangeable correlation structure. For
example, studies with a continuous repeated measures outcome may observe an autoregressive cor-
relation structure. However, the exchangeable working assumption can be employed conservatively
in the following way: if the hypothesized structure is not exchangeable, one approach is to set
ρ in formula (10) to the smallest plausible value (e.g., the within-person correlation between the
baseline and end-of-study measurements for an autoregressive structure). Because this approach
utilizes a lower bound on the value of the true within-person correlations, it is expected to yield a
larger than needed (more conservative) sample size. Similarly, if the true within-person correlation
is expected to differ by DTR, one approach is to employ the smallest plausible ρ. As with the third
recommendation, these recommendations are not unique to SMARTs; indeed, these strategies may
also be used to size standard two-arm randomized trials with repeated measures outcome.
In the case where Var(Y
(d)
t ) varies with time and/or DTR, we conjecture that power will suffer
if a pooled estimate of σ2 is used when the variance decreases with time. To see this, consider that
the standardized effect size δ defined in equation (9) has as a denominator the pooled standard
deviation of Y
(d)
2 across the groups under comparison. Should the estimate of pooled standard
deviation be larger than the true value, the variance of c>θˆ will increase; since the estimate will be
less efficient than hypothesized, power will be lower than expected. Conversely, we also conjecture
that when Var(Y
(d)
t ) increases with t, the sample size will be conservative using similar reasoning.
The main contribution of this manuscript is the development of sample size formulae for
SMARTs in which the primary aim is an end-of-study comparison of two embedded DTRs which rec-
ommend different first-stage treatments (so-called “separate-path” DTRs).46 It is possible, though,
that some trialists may have interest in sizing a SMART for an end-of-study comparison of “shared-
path” DTRs; that is, two DTRs which recommend the same first-stage treatment. We believe that,
for the comparison of shared-path DTRs, investigators are better set to use a standard sample size
calculation to compare the second-stage treatments which differ between the DTRs, then upweight-
ing the result by the proportion of participants expected to be in these groups.
There are a number of interesting ways to build on this manucript in future methodological work.
First, some scientists may be interested in a primary aim comparison that involves other features of
the marginal mean trajectory, such as the area under the curve (AUC). Future work could develop
formulae for these other primary aim comparisons. An important challenge here is in whether and
how to define the standardized effect size δ. Second, an interesting extension of this work is to
better understand the cost-benefit trade-off between adding additional sample size versus adding
additional measurement occasions to the SMART design. The formulae presented here employ the
rather simplistic working assumption that there are T = 3 measurement occasions (at baseline, the
end of the first stage, and the end of the second stage). Based on limited simulation experiments,
sample sizes based on our formulae are expected to perform conservatively when T > 3. Future
work could develop rules of thumb for how best to allocate additional sample size versus additional
measurement occasions given budget constraints (e.g., a fixed total study cost and fixed costs for
an additional participant and additional measurement occasion). Third, as the field moves toward
simulation-based approaches for sample size calculation, there is a clear need for the development of
software that would allow applied statistical workers and clinicians to make fewer (or more flexible)
assumptions concerning many of the features of the SMART, or to be more flexible with respect to
the design of the SMART. An important challenge here is to make the software general enough to
be used across a number of different types of SMART designs (e.g., three stages of randomization),
yet not so flexible that it is difficult to use. The benefits of this is the ability to examine the power
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for various different scientific questions given a single data generative model and for many other
types of SMARTs.
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Table A1: Design-specific consistency assumptions. d ∈ D indexes embedded DTRs
(a1, a2R, a2NR).
Design Y2,i
I
∑
d∈D
1
21{A1,i = a1} (Ri1{A2,i = a2R}+ (1−Ri)1{A2,i = a2NR})Y
(d)
2,i
II
∑
d∈D 1{A1,i = a1}
(
1
2Ri + (1−Ri)1{A2,i = a2}
)
Y
(d)
2,i
III
∑
d∈D 1{A1,i = a1}
(
1{a1 = −1}+ 1{a1 = 1}
(
1
2Ri + (1−Ri)1{A2,i = a2}
))
Y
(d)
2,i
The factor of 1/2 for responders in designs II and III accounts for the fact that these participants
are consistent with two DTRs. For example in design II, if Rj = 1 for some j, Y
(a1,0,1)
j =
Y
(a1,0,−1)
j := Y
(a1,0,·)
j .
A Identifiability Assumptions
We make the following assumptions in order to show that equation (4) has mean zero.
I1 Positivity. The probabilities P (A1 = 1) and P (A2 = 1 | A1, R) are non-zero.
I2 Consistency with potential outcomes.47 A participant’s observed responder status is “consistent”
with the participant’s corresponding potential responder status under the assigned first-stage
treatment; i.e.,
Ri = 1{A1,i = 1}R(1)i + 1{A1,i = −1}R(−1)i .
Furthermore, a participant’s observed repeated measures outcomes are consistent with the par-
ticipant’s corresponding potential repeated measures outcomes under the assigned treatment
sequence; see table A1.
I3 Sequential randomization. At each stage in the SMART, observed treatments A1 and A2 are
assigned independently of future potential outcomes, given the participant’s history up to that
point. That is,
{Y (d)i , R(a1)i } ⊥⊥ A1,i
{Y (d)i } ⊥⊥ A2,i | A1,i, Ri
Identifiability assumptions I1 and I3 are satisfied by design in a SMART (see, e.g., Lavori and
Dawson48); identifiability assumption I2 is connects the potential outcomes and observed data, and
is typically accepted in the analysis of randomized trials.
B Derivation of Sample Size Formulae
We derive the sample size formulae for comparing two DTRs which recommend different first-stage
treatments that are embedded in a SMART in which a continuous longitudinal outcome is collected
throughout the study. These formulae are based on the regression analyses described in section 3
and a Wald test.
We consider a SMART in which the outcome is collected at three timepoints: at baseline
(t1 = 0), immediately before assessing response/non-response (t2 = 1), and at the end of the study
(t3 = 2). We ignore the presence of baseline covariates X and assume µ
(d)(θ) is piecewise-linear in
θ (see, for example, model (1)). Recall that θ ∈ Rp.
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Recall from section 4 that we wish to the null hypothesis H0 : c
>θ = 0, where c ∈ Rp is a
contrast vector specifying a linear combination of θ. In particular, we are interested in contrasts c
which yield an end-of-study comparison between two embedded DTRs which recommend different
first-stage treatments. For example, in design II, the end-of-study comparison of DTRs (1, 0, 1)
vs. (-1, 0, -1) is given by c = (0, 0, 2, 0, 2, 2, 0)>. Since, here, c is a vector, this yields a 1-degree of
freedom Wald test for which we can use a Z statistic:
Z =
√
nc>θˆ
σc
,
where σc =
√
c>B−1MB−1c. Under H0, by asymptotic normality of
√
n(θˆ− θ), the test statistic
follows an asymptotic standard normal distribution. Suppose we wish to test H0 against the
alternative hypothesis c>θ = ∆. The minimum-required sample size is
n ≥ (z1−α/2 + z1−β)2 σ2c∆2 , (B1)
where zp is the pth quantile of the standard normal distribution. Formula (B1) is a standard result
in the clinical trials literature;41,49 however, because of the dependence on σc, the formula is not
useful as written. The goal of the remainder of this appendix is to derive a closed-form upper
bound on σc so as to obtain a sample size formula in terms of marginal quantities which can be
more easily elicited from clinicians, or estimated from the literature. In particular, we want this
upper bound to be a multiple of σ2, the assumed common marginal variance across time and DTR,
so that the final formula will involve Cohen’s effect size δ = ∆/σ.
Recall the definitions of B ∈ Rp×p and M ∈ Rp×p in equations (5) and (6), respectively. These
quantities depend on D(d) ∈ RT×p, the Jacobian of µ(d)(θ), and V (d)(τ ) ∈ RT×T , the working
covariance matrix for Y (d). By assumed linearity of µ(d)(θ), D(d) is a fixed, constant matrix for all
d. Furthermore, we assume that the working covariance matrix V (d)(τ ) is correctly specified and
satisfies working assumption A2 so that V (d)(τ ) = Σ for all d ∈ D. Note that Σ is non-random.
The estimand in equation (8) is a function of potential outcomes; as written in equations (5)
and (6), B and M are functions of observed data. We begin by expressing B in terms of potential
outcomes. Under the positivity, consistency, and sequential ignorability conditions (identifiability
assumptions I1 to I3), we can apply lemma 4.1 of Murphy et al.10 so that
B =
∑
d∈D
E
A1,R,A2
[
W (d)(A1, R,A2)D
(d)
(
V (d)(τ )
)−1 (
D(d)
)>]
=
∑
d∈D
D(d)Σ−1
(
D(d)
)>
. (B2)
We now turn our attention to M . Expanding the outer product inside the expectation, we have
M = E
A1,R,A2,Y
(∑
d∈D
W (d)(A1, R,A2)D
(d)
(
V (d)(τ )
)−1 (
Y − µ(d)(θ)
))⊗2
=
∑
d∈D
E
A1,R,A2,Y
[(
W (d)(A1, R,A2)
)2 (
D(d)Σ−1
(
Y − µ(d)(θ)
))⊗2]
+
∑
d6=d′
E
A1,R,A2,Y
[
W (d)(A1, R,A2)W
(d′)(A1, R,A2)D
(d)Σ−1
(
Y − µ(d)(θ)
)(
Y − µ(d′)(θ)
)>
Σ−1
(
D(d
′)
)>]
.
(B3)
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Consider a single summand of the first term in equation (B3). We can write this as
D(d)Σ−1 E
A1,R,A2,Y
[
W (d)(A1, R,A2)
2
(
Y − µ(d)(θ)
)⊗2]
Σ−1
(
D(d)
)>
, (B4)
where, as before, Z⊗2 = ZZ>. The inner expectation is a T × T matrix, the (i, j)th element of
which is
E
A1,R,A2,Y
[
W (d)(A1, R,A2)
2
(
Yti − µ(d)ti (θ)
)(
Ytj − µ(d)tj (θ)
)]
. (B5)
Notice that the work above is design-independent: B and M have the same form as equa-
tions (B2) and (B3), respectively, for all designs. Below, we proceed only for design II, but deriva-
tions for designs I and III are analogous, substituting appropriate definitions ofW (d)(A1, R,A2). Re-
call that, for design II, when all randomization probabilities are 0.5, W (d)(A1, R,A2) = 21
{
A1 = a
(d)
1
}
(R+
2(1−R)1
{
A2 = a
(d)
2
}
).
It can be shown that we can achieve an upper bound on σc which involves σ and ρ by imposing
working assumption A1 on the inner expectation in equation (B4) such that all diagonal terms are
at least 2 ·DE · σ2 and all off-diagonal terms are at most 2 ·DE · ρσ2, where DE is the design effect
as in table 3.
Consider, for example, t = 1. By repeated use of iterated expectation and application of
identifiability assumptions I2 and I3, equation (B5) becomes
E
Yt0 ,A1,Yt1 ,R,A2,Yt2
[
W (d)(A1, R,A2)
2
(
Yt1 − µ(d)t1 (θ)
)2]
= E
Yt0 ,A1,Yt1 ,R,A2
[
41
{
A1 = a
(d)
1
}(
R+ 4(1−R)1
{
A2 = a
(d)
2
})(
Yt1 − µ(d)t1 (θ)
)2]
= E
Y
(d)
t0
,A1,Yt1 ,R
(a1),A
(d)
2
[
41
{
A1 = a
(d)
1
}(
R(a1) + 4(1−R(a1))1
{
A2 = a
(d)
2
})(
Y
(d)
t1
− µ(d)t1 (θ)
)2]
= E
S2(A¯1)
[
41
{
A1 = a
(d)
1
}(
R(a1) + 4(1−R(a1)) E
A2|S2(A¯1)
[
1
{
A2 = a
(d)
2
}])(
Y
(d)
t1
− µ(d)t1 (θ)
)2]
= E
Y
(d)
t0
,A1,Y
(d)
t1
,R(a1)
[
41
{
A1 = a
(d)
1
}(
2−R(a1)
)(
Y
(d)
t1
− µ(d)t1 (θ)
)2]
. (B6)
= 4 E
Y
(d)
1
[(
Y1 − µ(d)1
)2]− 2 E
Y
(d)
1 ,R
(a1)
[(
Y1 − µ(d)1
)2
R(a1)
]
(B7)
= 4σ2 − 2 Cov
((
Y1 − µ(d)1
)2
, R(a1)
)
− 2 E
[
R(a1)
]
E
[(
Y1 − µ(d)1
)2]
(B8)
= 2(2− ra1)σ2. (B9)
Equation (B7) follows from equation (B6) by identifiability assumption I3 and smoothing over
Y
(d)
t0
, equation (B8) arises from the definition of covariance, and equation (B9) is a consequence of
working assumption A1(b).
Similar derivations can be performed for the remaining combinations (i, j). Under working
assumptions A1 and A2, equation (B5) is exactly equal to 2(2 − ra1)Σi,j for i, j ∈ {1, 2}. For the
last diagonal element (i = j = 3), equation (B5) is at least 2(2−ra1)Σ3,3; the remaining off-diagonal
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quantities are bounded above by 2(2− ra1)Σi,j . This allows us to bound c>B−1MB−1c above by
c>B−1MB−1c ≤ 2 · 1
2
((2− r1) + (2− r−1)) c>B−1
(∑
d∈D
D(d)Σ−1
)⊗2
B−1c
=
4σ2(1− ρ) (ρ2 + 4ρ− 12(r1 + r−1)(2ρ+ 1) + 2)
1 + ρ
. (B10)
Plugging equation (B10) into formula (B1) leads to the aforementioned “sharp” sample size
formula for design II. Some algebra shows that
σ2c ≤ 4σ2 ·
(
1− ρ2) · 1
2
((2− r1) + (2− r−1)) , (B11)
which allows for an easy-to-understand sample size formula. Plugging this result into formula (B1),
we arrive at formula (10).
C Details Concerning the Data-Generative Process for Simula-
tions
Authors’ note: this section has been almost entirely rewritten in an attempt to improve clarity.
We of course welcome any additional comments or feedback.
To construct table 4, we employ two data-generative models. Here, we describe the first, which
we believe to be more realistic and which is used to simulate under all scenarios in table 4 except
for those in which working assumption A1(c) is violated. A description of the second model, used
to violate working assumption A1(c), is available in the supplement.
In general, generating realistic longitudinal data from a SMART is difficult when precise control
must be exerted over the marginal covariance structure of the outcomes. As such, the generative
model described here is rather complex. We attempt to distill the details in this appendix and
provide further details about response status and variance generation in the supplement.
For each scenario described in table 4, we compute the sample size for the trial using formula (10)
and the appropriate design effect from table 3. We then, for each “participant” i, generate potential
outcomes under each embedded DTR as follows:
Y
(d)
0,i = γ0 + 0,i
Y
(d)
1,i | Y (d)0,i = γ0 + ρY (d)0,i + γ1 + γ2a1 + (a1)1,i
R
(a1)
i | Y (d)0,i , Y (d)1,i = ga1
(
Y
(a1)
1,i
)
Y
(d)
2,i | Y (d)0,i , Y (d)1,i , R(a1)i = (1− c0(ρ)− c1(ρ)) γ0 + c0(ρ)Y (d)0,i + c1(ρ)Y (d)1,i
+ (1− c1(ρ))
(
γ1 + γ2a
(d)
1
)
+ γ3 + γ4a
(d)
1 + ξ
(d)
(
R
(a1)
i
)
+
(
R(a1) − ra1,i
)(
λ1 + λ2a
(d)
1
)
+ 
(d)
2,i
(
R
(a1)
i
)
, (C1)
where 0 ∼ N
(
0, σ2
)
, 
(d)
1 ∼ N
(
0, (1− ρ2)σ2), and (d)2 (R(a1)i ) ∼ N (0, v(d)(R(a1)i )). σ2 =
Var(Y
(d)
t ) is the assumed constant marginal variance of the outcome as in working assumption A2.
Here, a
(d)
j is the jth-stage treatment recommended by DTR d.
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Table C1: Design-specific conditional mean components ξ(d)(R(a1)) for model (C1). ra1,i is the
probability of response to first-stage treatment for participant i. Dashes indicate that the corre-
sponding parameter is not used in the model for that design; variances in the lower part of the
table span across multiple rows when (non-)responders to the corresponding first-stage treatment
are not re-randomized.
Design ξ(d)
(
R(a1)
)
I
R(a1)
ra1,i
(
γ5 + γ7a
(d)
1
)
a
(d)
2R +
1−R(a1)
1− ra1,i
(
γ6 + γ8a
(d)
1
)
a
(d)
2NR
II
1−R(a1)
1− ra1,i
(
γ5 + γ6a
(d)
1
)
a
(d)
2NR
III
1−R(a1)
1− ra1,i
1
{
a
(d)
1 = 1
}
· γ5a(d)2NR
The error terms t add the “additional” variance to Y
(d)
j which is needed to achieve marginal
variance σ2. Outcomes Y
(d)
t,i are generated as functions of an individual’s outcomes at previous
timepoints, which induces variance in, say, Y
(d)
2 when marginalizing over Y
(d)
1 and Y
(d)
0 . Hence,
v(d)(R(a1)) is the additional variance added to the response-conditional end-of-study outcome be-
yond that which is induced by defining Y
(d)
2,i | R(a1)i as a function of Y (d)0,i and Y (d)1,i . This is required
to ensure that the marginal variance of Y
(d)
2 is σ
2. All errors  are generated independently of one
another.
The parameters γj are interpreted exactly as in, say, model (1) (see section 3.3 and equation (2)),
and index the generative marginal structural mean model. The functions ct(ρ) control within-person
correlation between Y
(d)
2,i and previously-observed outcomes Y
(d)
t,i , t < t
∗. For an exchangeable
correlation structure, we use c0(ρ) = c1(ρ) = ρ/(1 + ρ); for AR(1), c0(ρ) = 0 and c1(ρ) = ρ.
Note that the second-stage outcome Y
(d)
2,i is generated conditionally on response status, since
participants in a SMART can only be a responder or a non-responder to first-stage treatment. Since
second-stage treatments in a SMART are often restricted based on response, these treatment effects
can typically only be estimated using either responders or non-responders. ξ(d)(R(a1)) is a design-
specific function of response which involves marginal parameters γj for second-stage treatment
effects and their interactions with first-stage treatment effects. Our choices of ξ(d)(R(a1)) are given
in table C1. For example, in design II, only non-responders are re-randomized, and so the effect
of a2NR should only be simulated among non-responders, and upweighted appropriately to reflect
this (see table C1).
The final component of the generative mean structure for Y
(d)
2,i | R(a1)i is (R(a1)i − ra1,i)(λ1 +
λ2a
(d)
1 ), where ra1,i is the probability of response to first-stage treatment for participant i. The
parameters λ1 and λ2 control how responders and non-responders differ from the marginal mean
at time 2, and cancels to zero when averaged over response status.
In order to design a realistic generative model, we define response as a function of Y
(a1)
1,i . In
table 4, we consider three possible response models: “R⊥⊥”, in which response status is independent
of Y
(a1)
1,i , “R+”, in which P (R
(a1)
i = 1) increases with Y
(a1)
1,i , and “R−”, in which P (R
(a1)
i = 1) is
decreasing in Y
(a1)
1,i . In figure C1, we plot probabilities of response versus Y
(d)
1,i under both R+ and
R− response models. We consider both R+ and R− to ensure that power is not affected by the
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Table C2: Example choices of parameters in data generative model to achieve δ = 0.3 and ρ = 0.3
when r1 = r−1 = 0.4 under R+ and working assumptions A1 and A2 are satisfied for each of
designs I to III.
Parameter Design I Design II Design III
γ0 35.0 33.5 35.0
γ1 -4.0 -0.8 -0.5
γ2 2.7 0.9 1.0
γ3 -1.6 -0.8 0.2
γ4 -1.5 0.4 -0.2
γ5 0.4 -0.4 0.8
γ6 -0.4 0.1 –
γ7 0.4 – –
γ8 0.4 – –
λ1 0.3 0.1 0.8
λ2 0.4 -0.5 0.0
σ2 64 36 64
v(1,1,a2NR)(1) 57.62
21.12 56.56
v(1,−1,a2NR)(1) 57.62
v(1,a2R,1)(0) 53.07 18.48 55.27
v(1,a2R,−1)(0) 53.07 21.64 43.37
v(−1,1,a2NR)(1) 57.89
19.39 53.68
v(−1,−1,a2NR)(1) 57.89
v(−1,a2R,1)(0) 49.80 14.20
53.97
v(−1,a2R,−1)(0) 55.78 20.80
28
Figure C1: Individual probabilities of response versus potential outcomes at the end of the first
stage of a SMART under response models R+ and R−. Based on a simulated SMART with n = 500
individuals; a1 = 1 was chosen arbitrarily and without loss of generality. Empirical average response
rate is plotted as a horizontal line in gray. Darker regions of the curve contain more observations.
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(I) Response probabilities in the R+ model versus
Y
(1)
1,i with average response rate r1 = 0.4. Higher val-
ues of Y
(1)
1,i are associated with higher response prob-
abilities.
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(II) Response probabilities in the R− model versus
Y
(1)
1,i with average response rate r1 = 0.6. Higher val-
ues of Y
(1)
1,i are associated with lower response prob-
abilities.
choice of coding for Y (e.g., “higher-is-better” vs. “lower-is-better”). More details are provided in
the supplement.
The above models are used to generate potential outcomes Y
(d)
i and potential response status
R
(a1)
i for each “participant” under each DTR d = (a1, a2R, a2NR). This is done to ensure the
generative model satisfies identifiability assumption I2; identifiability assumptions I1 and I3 are
satisfied by design. From these potential data, we “observe” data as follows:
1. Choose Y0,i = Y
(d)
0,i . Note that since no treatment has been assigned at time 0, there is only
one possible value of Y0, so the potential and observed outcomes coincide.
2. Generate A1,i ∼ Bernoulli(0.5).
3. Choose Y1,i = Y
(A1,i,·,·)
1,i , the potential outcome at time 1 corresponding to the DTR(s) which
recommend first-stage treatment A1,i.
4. Choose Ri = R
(A1,i), the potential response status of the participant under first-stage treat-
ment A1,i.
5. Generate A2,i | Ri ∼ Bernoulli(pi), where pi is either 0.5 or 0 depending on the value of Ri
and the SMART design under consideration. (For example, in design II, pi = 0 for all i such
that Ri = 1 since responders are not re-randomized.)
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Table C3: Target and estimated marginal variance matrices V (d)(τ ) from the data generative model
described in appendix C. The “unstructured estimate” is produced by estimating the variance at
each timepoint and for each DTR, and correlation for each DTR using the unstructured estimate in
table 2, then averaging over DTRs. The “exchangeable estimate” is computed by assuming variance
is constant over time and DTR, and using the exchangeable estimate of ρ from table 2, averaged
over DTRs. The exchangeable estimate is used in simulations assuming working assumption A2 is
satisifed.
Design Target Structure Unstructured Estimate Exchangeable Estimate
I
 64 19.2 19.219.2 64 19.2
19.2 19.2 64
 63.9 19.3 19.119.3 63.8 18.7
19.1 18.7 62.5
 63.4 18.9 18.918.9 63.4 18.9
18.9 18.9 63.4

II
 36 10.8 10.810.8 36 10.8
10.8 10.8 36
 35.9 10.9 11.010.9 35.9 11.1
11.0 11.1 35.8
 35.9 10.9 10.910.9 35.9 10.9
10.9 10.9 35.9

III
 64 19.2 19.219.2 64 19.2
19.2 19.2 64
 63.9 19.4 19.919.4 63.7 21.3
19.9 21.3 63.6
 63.8 20.0 20.020.0 63.8 20.0
20.0 20.0 63.8

6. Choose Y2,i | R(A1,i) = Y (A1,i,R
(A1,i)A2,i),(1−R(A1,i))A2,i)
2,i , the potential outcome at time 2 had the
participant had response status Ri and been treated according to a DTR which recommends
A1,i in the first stage and A2,i in the second.
In table C2 we provide values of the parameters chosen for simulations to achieve a standardized
effect size δ = 0.3 for the end-of-study comparison of interest. The values of v(d)(R(a1)) are specific
to the scenario in which all working assumptions are satisfied, ρ = 0.3, average response probabilities
are r1 = r−1 = 0.4, and when response is computed under the R+ model. In table C3, we show
that the target marginal variance structures are achieved using this data generative model.
30
